DexCom's growth rate has been improving, but that hasn't been enough of a reason for investors to buy up the stock.

DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is ...

Morgan Stanley lowered the firm’s price target on DexCom (DXCM) to $63 from $89 and keeps an Overweight rating on the shares. Published first on ...

Shares have lagged the market this year, partly due to some public image and regulatory issues. DexCom's stock could drop even more if results falls short of revenue expectations. Whatever happens on ...

SAN DIEGO, October 27, 2025--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Euan Ashley to its Board of Directors, effective ...

A trio of stocks made an impressive leap in their Benzinga Edge value scores this week, with one standout making a 138% jump.

People with Type 1 diabetes are estimated to make up to 180 more decisions a day than someone without the disease, according to a study from Stanford University. Each meal, workout, or night’s sleep ...

Bullish option flow detected in DexCom (DXCM) with 4,618 calls trading, 1.3x expected, and implied vol increasing almost 3 points to 63.76%. Dec-25 85 calls and 10/24 weekly 73 calls are the most ...

The company’s strong financial health score of "GREAT" on InvestingPro supports this outlook, with robust cash flows and moderate debt levels. TD Cowen expects DexCom’s upcoming third-quarter results ...

Investing.com -- DexCom (NASDAQ:DXCM) stock fell 4% Tuesday after a concerning report from Hunterbrook detailed multiple deaths allegedly linked to the company’s G7 continuous glucose monitor. The ...